Perspective
Jan. 8, 2014
The state of life sciences product liability
Ongoing developments regarding three key areas continue to impact manufacturers of medical devices, drugs and biologics. By Cheryl A. Sabnis
Product liability litigation remains a substantial threat to a life science company's most valuable assets - the drugs, biologics and devices they manufacture. While the war over pre-emption rages, a manufacturer's promotional efforts continue to guide plaintiffs around the defenses manufacturers traditionally have used to avoid liability for product-associated injuries, including the learned intermediary doctrine. Meanwhile, pre-empti...
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In